Stock A214390 KYONGBO PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Kyongbo Pharmaceutical Co., Ltd Stock

Equities

A214390

KR7214390007

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 19:00:00 2024-03-26 EDT 		5-day change 1st Jan Change
7,440 KRW -2.75% Intraday chart for Kyongbo Pharmaceutical Co., Ltd -.--% -11.32%
2023 Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd CI
2023 Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Financials

Sales 2022 196B 142M 195M Sales 2023 216B 156M 215M Capitalization 201B 145M 199M
Net income 2022 611M 441K 607K Net income 2023 2.97B 2.14M 2.96M EV / Sales 2022 1.51 x
Net Debt 2022 57.29B 41.31M 56.95M Net Debt 2023 70.59B 50.89M 70.17M EV / Sales 2023 1.25 x
P/E ratio 2022
392 x
P/E ratio 2023
67.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 38.1%
More Fundamentals * Assessed data

Chart Kyongbo Pharmaceutical Co., Ltd

Dynamic Chart

Latest news about Kyongbo Pharmaceutical Co., Ltd

Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd CI
Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pharosgen Co., Ltd. announced that it expects to receive KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd CI
Kyongbo Pharmaceutical Co., Ltd(KOSE:A214390) dropped from S&P Global BMI Index CI
Can-Fite BioPharma Ltd. Signs Distribution Agreement with Kyongbo Pharm Co., Ltd CI
AFT Pharmaceuticals Limited Starts to License Maxigesic IV with Deal in South Korea CI
Chong Kun Dang Holdings Corp. cancelled the acquisition of an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd.. CI
Chong Kun Dang Holdings Corp. agreed to acquire an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd. for KRW 19.7 billion. CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to Russell Global Index CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to S&P Global BMI Index CI
Kyongbo Pharmaceutical Co., Ltd. has completed an IPO in the amount of KRW 143.44 billion. CI
Kyongbo Pharmaceutical Co. Ltd. has filed an IPO in the amount of KRW 143.45 billion. CI
More news

News in other languages on Kyongbo Pharmaceutical Co., Ltd

MIDDAY BRIEFING - Unternehmen und Märkte
MÄRKTE ASIEN/Coronasorgen belasten Börsen nur zum Teil
MÄRKTE ASIEN/Impfstoff-Hoffnung und Biden-Amtsübergabe stützt
MÄRKTE ASIEN/Wenig veränderte Börsen mit positiver Tendenz
More news

Quotes and Performance

1 day-2.75%
3 months-5.94%
6 months+15.35%
Current year-11.32%
More quotes

Highs and lows

Current year
6 630.00
Extreme 6630
8 480.00
1 year
6 060.00
Extreme 6060
10 950.00
3 years
4 875.00
Extreme 4875
15 300.00
5 years
4 580.00
Extreme 4580
22 600.00
10 years
4 580.00
Extreme 4580
38 500.00
More quotes

Managers and Directors - Kyongbo Pharmaceutical Co., Ltd

Managers TitleAgeSince
Tae-Young Kim CEO
 Chief Executive Officer 65 -
Byung-Ok Kim CTO
 Chief Tech/Sci/R&D Officer 53 -
Jae-Taek Hwang CTO
 Chief Tech/Sci/R&D Officer 60 -
Members of the board TitleAgeSince
Tae-Young Kim CEO
 Chief Executive Officer 65 -
Saeng-Gyu Seo BRD
 Director/Board Member 65 -
Jae-Taek Hwang CTO
 Chief Tech/Sci/R&D Officer 60 -
More insiders

Company Profile

KYONGBO PHARMACEUTICAL CO., LTD is a Korea-based company principally engaged in manufacturing and distributing pharmaceutical products The Company operates its business through two segments: raw material medicine segment, which produces atorvastatin, ceftizoxime, ceftriaxone, clarithromycin and Pranlukast, and medicine segment, which produces surgeon respiratory solution, cefaclor capsule and cefaclor dry syrup. The Company distributes its products within domestic market and to overseas markets including China Japan and Europe.
Sector
Pharmaceuticals
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
KYONGBO PHARMACEUTICAL CO., LTD Stock Kyongbo Pharmaceutical Co., Ltd
-11.32% 129M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-4.89% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A214390 Stock